Nolvadex is the original brand name of tamoxifen, a selective estrogen receptor modulator (SERM). In men it blocks estrogen’s brake on the brain, so LH, FSH and testosterone rise: in 10 healthy men, two weeks of tamoxifen raised testosterone by about 40% and LH by about 70% (Birzniece 2010). That is why it is used for PCT after SARMs or steroids.
What has not been shown: no trial has tested tamoxifen as PCT after SARMs or steroids, and a 2026 review describes the evidence for post-cycle therapy in general as limited and mostly observational (Smit 2026). Its best-proven use in men is different: preventing breast growth caused by anti-androgen drugs (Boccardo 2005). Below: how it works, the doses studies used, what is known about using it after or during a SARM cycle, side effects and legal status.
What is Nolvadex?

Tamoxifen is a SERM: it binds estrogen receptors and blocks them in some tissues (breast, the hypothalamus) while acting more like estrogen in others. FDA first approved Nolvadex on 30 December 1977 (Drugs@FDA). The US label covers metastatic breast cancer in women and men, treatment after breast cancer surgery, DCIS, and lowering breast cancer risk in high-risk women (label). Use for gynecomastia, male infertility or after a cycle is off-label.
In men, three effects matter for PCT:
- LH, FSH and testosterone go up. Testosterone +40% and LH +70% in healthy men (Birzniece 2010). In 94 subfertile men, tamoxifen 20 mg/day raised gonadotropins more than raloxifene (Tsourdi 2009).
- SHBG goes up. SHBG rose about 20% in healthy men (Birzniece 2010). In men on bicalutamide, total testosterone rose but free testosterone did not change, because SHBG rose with it (Boccardo 2005).
- IGF-1 goes down. About 25% lower after two weeks at 20 mg/day; raloxifene did not lower it (Birzniece 2010).
For how tamoxifen compares with the other options, see SARMs PCT and 13 things to know about SERMs.
Nolvadex legal status
| Where | Status |
|---|---|
| United States | Prescription-only medicine. Approved for breast cancer treatment and risk reduction; other uses in men are off-label (label). |
| Germany | Listed in the Anti-Doping Act annex: acquiring or possessing a “non-small quantity” for doping in sport is an offense (AntiDopG). |
| Sport (WADA) | Prohibited at all times under S4.2, anti-estrogenic substances; a specified substance (WADA 2026). |
For SARMs themselves, see are SARMs legal.
Nolvadex dosage: what studies used
No study has tested a tamoxifen dose for recovery after SARMs or steroids. These are the doses used in studies of men, and what happened:
| Dose | Who | How long | What happened |
|---|---|---|---|
| 10 and 20 mg/day | 10 healthy men | 2 weeks each | Testosterone up about 40%, LH up about 70%, SHBG up 20% and IGF-1 down 25% at the higher dose (Birzniece 2010) |
| 20 mg/day | 94 subfertile men | Not stated in the abstract | Gonadotropins rose, more than with raloxifene (Tsourdi 2009) |
| 20 mg/day (with bicalutamide) | 114 men with prostate cancer | 48 weeks | Breast growth in 10% vs 73% on placebo and 51% on anastrozole (Boccardo 2005) |
| 1, 2.5, 5, 10 or 20 mg/day (with bicalutamide) | 282 men with prostate cancer | 12 months | Breast events at 6 months fell from 86.2% (1 mg) to 8.8% (20 mg), vs 96.7% on placebo; hot flushes rose from 5 mg/day (Fradet 2007) |
PCT guides online, including older versions of this page, describe 20–40 mg/day for about four weeks. That is anecdotal: no study has tested it.
How long it lasts. Tamoxifen has a half-life of about 5–7 days, and its main active metabolite, N-desmethyltamoxifen, about 14 days. Steady state takes about 4 weeks for tamoxifen and about 8 weeks for the metabolite (label). So a short course is still in the body weeks after the last capsule. The PCT & Bloodwork Planner shows clearance times side by side.
How Nolvadex is used after SARMs, and what the evidence says
People use tamoxifen after a SARM cycle to push LH and testosterone back up. The pieces of evidence that exist:
- SARMs suppress, and recover. LGD-4033 lowered testosterone at 0.1–1 mg/day, and levels were back to baseline five weeks after stopping without treatment (Basaria 2013). Ostarine lowered total testosterone at 1–3 mg/day (Dalton 2011). See the evidence for each SARM.
- Tamoxifen raises testosterone in men with a working hormone axis (Birzniece 2010). Whether that speeds recovery after SARMs has not been tested.
- After steroids, the observational PCT data are mostly for clomiphene, not tamoxifen (İbis 2026), (Grant 2023).
Timing. No study defines when to start. A SERM taken while a SARM is still in the body works against a drug that is still suppressing. After five half-lives about 3% of a drug is left (StatPearls): roughly 5–8 days for LGD-4033 and 3–5 days for ostarine, based on their measured half-lives.
Checking. The way to see whether suppression is still there is a blood test after the SARM has cleared: total testosterone (fasting, in the morning), LH, FSH and SHBG. Because tamoxifen itself raises SHBG, free testosterone is useful too (Bhasin 2018). See SARMs bloodwork.
Can you take Nolvadex while on SARMs?
No study has tested tamoxifen together with a SARM. The closest data are from men taking the anti-androgen bicalutamide, where tamoxifen 20 mg/day taken alongside it for 48 weeks prevented most breast growth (Boccardo 2005). That is the evidence behind using it “on cycle” against gyno, but bicalutamide blocks the androgen receptor while SARMs activate it, so the results may not transfer. Older versions of this page advised never combining a SARM with PCT drugs and starting PCT only after the cycle; that advice was not based on a study either.
For breast growth on SARMs, see do SARMs cause gyno and the raloxifene guide.
Nolvadex vs Clomid vs enclomiphene
| Tamoxifen (Nolvadex) | Clomiphene (Clomid) | Enclomiphene | |
|---|---|---|---|
| Approved for | Breast cancer (women and men) | Ovulation problems in women | Nothing |
| Male data | Small hormone studies; strong trials for preventing drug-induced breast growth | Meta-analysis of 19 studies in men with low testosterone (Huijben 2022); observational data after steroids | Phase 2 and 3 trials in secondary hypogonadism (EMA 2018) |
| Half-life | 5–7 days | Zuclomiphene part builds up and lingers for weeks (label) | 8–10 hours |
| Key risks | Blood clots, stroke, liver changes, lower libido | Visual symptoms, mood changes | Blood clots, blurred vision |
| Fact sheet | This page | Clomiphene for men, Clomid PCT | Enclomiphene for men |
No trial has compared tamoxifen and clomiphene for recovery after SARMs or steroids.
Tamoxifen vs aromatase inhibitors for breast growth
Both are used against estrogen effects, but they did not perform the same. In men on bicalutamide, breast growth occurred in 10% on tamoxifen, 51% on anastrozole and 73% on placebo (Boccardo 2005). A 2025 meta-analysis of nine trials found tamoxifen cut the risk of breast growth and breast pain by about 82%, while anastrozole showed no significant benefit (Spagnolo 2025). Evidence for tamoxifen in teenage (pubertal) gynecomastia is weaker: six studies, none randomized (Lapid 2013). More on anastrozole: anastrozole for men.
Nolvadex side effects
| Side effect | What the evidence says | Evidence |
|---|---|---|
| Blood clots (DVT, pulmonary embolism) and stroke | More clotting events on tamoxifen. In the NSABP P-1 trial in women, pulmonary emboli occurred in 18 vs 6 on placebo. The boxed warning covers uterine cancer, stroke and pulmonary embolism in the risk-reduction setting (label). | Trial |
| Loss of libido and impotence | The label says these have led some male patients to stop tamoxifen (label). | Trial |
| Hot flushes | Rose at doses of 5 mg/day or more in men on bicalutamide (Fradet 2007). | Trial |
| Liver changes | Liver enzyme changes and, rarely, fatty liver, cholestasis, hepatitis and liver necrosis. The label advises periodic liver tests and blood counts (label). | Trial |
| Eye changes | Corneal changes, reduced color vision, retinal vein thrombosis, retinopathy and a borderline rise in cataracts (label). | Trial |
| Overall tolerability in men | Fewer than 5% of men stopped because of side effects; fewer side effects in men treated for infertility or gynecomastia than in men with cancer (Wibowo 2016). | Observational |
The clot and liver warnings are the ones most relevant to anyone with a history of blood clots or liver disease.
Nolvadex in drug tests
Tamoxifen is banned in sport at all times (WADA 2026). Anti-doping labs detect its metabolites in urine; six metabolites were found after a single 20 mg dose (Mazzarino 2010). No verified study defines a detection window. With a 5–7 day half-life and a 14-day metabolite, it stays in the body for weeks.
Where to buy Nolvadex
Tamoxifen is a prescription medicine in the US. Sarmguide’s current pick for research-grade tamoxifen is SwissChems Tamoxifen 20 mg, 60 capsules. SwissChems says each batch is tested by accredited third-party labs, mainly Janoshik Analytical, using HPLC, with a certificate of analysis (COA) per batch, and that a batch must test within 10% of the labeled amount (SwissChems FAQ page, checked 30 October 2026). It sells the product for laboratory research use only. Check that the COA you see matches your batch number.
Why we picked SwissChems: SwissChems review. Other PCT compounds: Buy PCT.
Bottom line
Tamoxifen reliably raises LH and testosterone in men and is the best-tested drug for preventing drug-induced breast growth. Its use as PCT after SARMs rests on that mechanism, not on a trial. It stays in the body for weeks and carries real risks, mainly blood clots, liver changes and sexual side effects in men. A blood test after the SARM has cleared is how suppression is measured.
Charts
| Dose studied | Who took part | Duration | What the study found | Source |
|---|---|---|---|---|
| 20 mg/day (with bicalutamide 150 mg/day) | 114 men with prostate cancer; randomized, double-blind vs placebo and vs anastrozole 1 mg/day | 48 weeks | Gynecomastia in 10% on tamoxifen vs 73% on placebo and 51% on anastrozole. Breast pain in 6% vs 39% and 27%. Adverse events were not increased with tamoxifen. | PubMed 2005 |
| 1, 2.5, 5, 10 or 20 mg/day (with bicalutamide 150 mg/day) | 282 men with prostate cancer; randomized, placebo-controlled dose-response study | 12 months | Breast events at 6 months: 86.2%, 60.0%, 55.3%, 23.5% and 8.8% on the five doses vs 96.7% on placebo. Hot flushes increased at doses of 5 mg or more. | PubMed 2007 |
| 10 and 20 mg/day (crossover with raloxifene 60 and 120 mg/day) | 10 healthy men; randomized open-label crossover | 2 weeks per dose | At the higher dose, IGF-1 fell 25% and SHBG rose 20%. Testosterone rose about 40% and LH about 70%, more than with raloxifene. | PubMed 2010 |
| 20 mg/day | 94 subfertile men with idiopathic oligozoospermia (part of a 284-man comparison with toremifene and raloxifene) | Not stated in abstract | Gonadotropin levels rose significantly, more than with raloxifene. | PubMed 2009 |
Sources: the studies linked in the table.
Source: Sarmguide compound database; Tamoxifen value: Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan) (2026).
More on Tamoxifen
Frequently asked questions
What is Nolvadex?
Tamoxifen, a SERMEvidence: Law
Nolvadex is the original brand name of tamoxifen, a selective estrogen receptor modulator (SERM) approved by the FDA in 1977 for breast cancer in women and men. It is not a SARM.
How much Nolvadex do people take for PCT?
No dose tested for PCTEvidence: Trial
No study has tested a tamoxifen dose for recovery after SARMs or steroids. Studies in men used 10–20 mg/day, and the schedules in online PCT guides are anecdotal.
Can you take Nolvadex while on SARMs or only for PCT?
Never tested with a SARMEvidence: Trial
No study has tested tamoxifen together with a SARM. In men on the anti-androgen bicalutamide, 20 mg/day for 48 weeks prevented most breast growth (10% vs 73% on placebo), but bicalutamide blocks the androgen receptor while SARMs activate it.
Is Nolvadex enough for PCT?
Unknown; no trialEvidence: Trial
No trial answers it; tamoxifen raises LH and testosterone in men with a working hormone axis. In the one SARM trial that followed people after stopping (LGD-4033 at up to 1 mg/day for 21 days), hormones recovered within five weeks without treatment.
Nolvadex or Clomid for PCT?
Never comparedEvidence: Human data
No trial has compared them for recovery after SARMs or steroids, and the observational post-steroid data are mostly for clomiphene. Clomiphene carries a warning about visual symptoms; tamoxifen about blood clots and stroke.
How long does tamoxifen stay in your system?
Weeks; half-life 5–7 daysEvidence: Human data
Tamoxifen has a half-life of about 5–7 days and its main metabolite, N-desmethyltamoxifen, about 14 days. Steady state takes about 4 weeks for tamoxifen and 8 weeks for the metabolite.
What are the side effects of Nolvadex in men?
Clots, stroke, liver, libidoEvidence: Trial
The label warns about blood clots and stroke, reports liver enzyme and eye changes, and says loss of libido and impotence have led some men to stop. Hot flushes increased at 5 mg/day or more in one male trial.
Does tamoxifen raise testosterone?
Yes, in studies of menEvidence: Human data
In 10 healthy men, tamoxifen raised testosterone about 40% and LH about 70% over two weeks. It also raised SHBG about 20%, so free testosterone rises less than total testosterone.
Does tamoxifen lower IGF-1?
Yes, about 25%Evidence: Human data
In healthy men, 20 mg/day lowered IGF-1 by about 25% over two weeks. Raloxifene did not.
Is tamoxifen banned in sport?
Yes, banned by WADAEvidence: Law
WADA lists tamoxifen under S4.2 (anti-estrogenic substances), prohibited at all times.
Is SwissChems Nolvadex legit?
Seller says batches are testedEvidence: Limited
SwissChems sells tamoxifen 20 mg capsules for laboratory research use and says every batch is tested by accredited third-party labs, mainly Janoshik Analytical, using HPLC, with a 10% tolerance on the labeled amount. Check that the COA matches the batch number.
Sources
- Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men
- Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives
- Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
- Drugs@FDA: NOLVADEX, NDA 017970
- Tamoxifen citrate tablets – prescribing information (DailyMed, Mylan)
- The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia
- Anlage zum Anti-Doping-Gesetz (AntiDopG), BGBl. 2023 I Nr. 67
- World Anti-Doping Code International Standard: Prohibited List 2026
- Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- Post-cycle therapy after short-term anabolic-androgenic steroid use: comparative outcomes in recreational bodybuilders
- Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study
- Elimination Half-Life of Drugs (StatPearls, NCBI Bookshelf)
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
- Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis
- EnCyzix (enclomifene): public assessment report, EMA/88321/2018
- CLOMID (clomiphene citrate) tablets – prescribing information (DailyMed)
- Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials
- Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review
- Tamoxifen in men: a review of adverse events
- Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry